Evidence Level:Sensitive: A2 - Guideline
New
Excerpt:Colon Cancer...SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE - CHEMOTHERAPY REGIMENS...FOLFIRINOX or mFOLFIRINOX + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...Irinotecan + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFOX + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)...FOLFIRI + cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only)
Secondary therapy:FOLFOX; FOLFIRINOX; FOLFIRI; irinotecan
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Medical Records Based Real-World Study of Cetuximab in Combination with FOLFIRI Regimen as First-Line Chemotherapy and Subsequent Cetuximab-based Maintenance Therapy for the Maintenance Treatment of Patients with RAS and BRAF Wild-Type Unresectable Metastatic Colorectal Cancer
Excerpt:...Subjects must meet all of the following criteria to be included in this retrospective study: A. Aged 18 to 75 years, male or female; B. histologically diagnosed adenocarcinoma of the colon or rectum; C. metastatic disease (not amenable to curative resection); D. RAS and BRAF wild-type; E. complete imaging assessment data: including baseline and PD data confirmed by CT or MRI; F. treated with the study's specified treatment regimen....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
FOLFIRI plus cetuximab as first-line therapy followed by cetuximab maintenance therapy in patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer: a single institute study
Excerpt:...RAS and BRAF wild type; 5. ...
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
study to investigate cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing after an initial response to a 1st-line cetuximab-containing therapy and a standard 2nd-line. studio per valutare un ritrattamento con cetuximab e irinotecano in pazienti con tumore del colon-retto metastatico KRAS, NRAS e BRAF wild-type, irinotecano resistenti, progrediti ad una prima linea a base di irinotecano (FOLFIRI o FOLFOXIRI) contenente cetuximab dalla quale abbiano ricevuto un iniziale beneficio
Excerpt:...Histologically proven diagnosis of colorectal adenocarcinoma; RAS and BRAF wild-type status of primary colorectal cancer and/or related metastasis; First-line irinotecan-based (FOLFIRI or FOLFOXIRI) cetuximab-containing therapy producing at least a partial response; First-line progression-free survival in response to cetuximab-containing therapy ≥6 months; Documentation of progression to first-line cetuximab within 4 weeks after last cetuximab administration; Time between the end of first-line therapy and the start of third-line treatment with cetuximab plus irinotecan ≥4 months; Second-line oxaliplatin-based (FOLFOXIRI, FOLFOX or XELOX) bevacizumab-containing therapy; Documentation of progression to second-line treatment; Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST criteria, vers.1.1); Have tumor tissue (of primary tumor and metastases or at least one of the two) available for biomarker analysis; Male or female, aged > 18 years of age; ECOG Performance Status ≤ 2; Life expectancy of at least 3 months; Adequate bone marrow, liver and renal function assessed within 14 days before starting study treatment; Signed informed consent obtained before any study specific procedures....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer
Excerpt:...Patients who have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, excluding appendix carcinoma or anal canal carcinoma, with RAS and BRAF wild-type mutation status....
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Nordic 8 - A Phase II Trial
Excerpt:...- Tumour tissue (primary or metastasis) typed as wild-type KRAS AND wild-type BRAF...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line. Studio CAPRI 2 GOIM: studio sull’efficacia e la sicurezza del regime di trattamento basato su cetuximab e guidato da biomarcatori su 3 linee di trattamento in pazienti affetti da carcinoma del colonretto metastatico che presentano uno stato Wild Type di RAS e BRAF prima dell’inizio del trattamento di prima linea
Excerpt:...RAS and BRAF wild-type status of FFPE analysis of primary colorectal cancer and/or related metastasis4. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Peripheral blood ctDNA second-generation sequencing to guide RAS/BRAF wild type: A clinical study of cetuximab re-challenge in patients with metastatic colorectal cancer
Excerpt:...Patients with pathologically confirmed advanced adenocarcinoma of the colon or rectum; initial tissue RAS/BRAF wild type; 2. ...
Evidence Level:Sensitive: C2 – Inclusion Criteria
New
Title:
Alternating chemotherapy plus cetuximab to allow resection of metastases from a colorectal cancer that is wild-type KRAS and BRAF - a randomised phase II trial - Nordic 7.6
Excerpt:...KRAS and BRAF status - Tumour tissue (primary or metastasis) typed as wild-type KRAS AND wild-type BRAF General conditions - age > 18 years - WHO performance status ≤ 1; - expected survival > 3 months - sufficient bone-marrow function (Hb ≥ 6.2 µmol/l/Hb > 10 g/dl ANC ≥ 1.5 x 109/l, thrombocytes ≥ 100 x 109/l) - sufficient kidney and liver function: total bilirubin ≤ 1.5 x upper normal limit, serum creatinine ≤ 1.25 x upper normal limit, ALAT ≤ 3 x upper normal limit and ≤ 5 x upper normal limit with liver metastases - the patient must have signed an informed declaration of consent before being registered; this must be documentable according to national guidelines...
